What is the recommended treatment for a Klebsiella infection, including options for ESBL‑producing strains, urinary tract infection, penicillin allergy, and resistant isolates?

Treatment of Klebsiella Infections

For severe Klebsiella infections (bloodstream infections, septic shock), use carbapenems (imipenem or meropenem) as first-line therapy; for non-severe urinary tract infections, consider oral alternatives including pivmecillinam, fosfomycin, or nitrofurantoin based on susceptibility testing. 1

Severe Infections and Bloodstream Infections

For patients with bloodstream infections or severe infections due to third-generation cephalosporin-resistant Klebsiella (which includes ESBL-producing strains):

• Use carbapenems (imipenem or meropenem) as targeted therapy 1
• If the patient does NOT have septic shock, ertapenem may be substituted for imipenem or meropenem 1
• Once the patient stabilizes, step down to oral therapy based on susceptibility results using older beta-lactam/beta-lactamase inhibitors, quinolones, or cotrimoxazole 1

ESBL-Producing Klebsiella in Urinary Tract Infections

Non-Severe UTIs (Cystitis, Lower UTI)

The evidence strongly supports several oral options that avoid carbapenem use:

First-line oral options:

• Pivmecillinam: Shows 78-83% bacteriological cure rates for ESBL-producing Klebsiella 2, with 83% sensitivity demonstrated in recent surveillance 3
• Fosfomycin: 36.5-62% susceptibility for ESBL-producing Klebsiella 3, 4, though notably lower than for E. coli
• Nitrofurantoin: 42% sensitivity for Klebsiella species 3 - significantly lower than for E. coli, making this less reliable

Important caveat: Klebsiella shows substantially lower susceptibility to these agents compared to E. coli, particularly for fosfomycin (36-62% vs 95-96%) and nitrofurantoin (42% vs 93%) 3, 4.

High-dose amoxicillin-clavulanate is an emerging option: Start with 2875 mg amoxicillin + 125 mg clavulanic acid twice daily, then down-titrate every 7-14 days 5. This showed 84.7% success in one study 6, though therapeutic failure is significantly more common with Klebsiella than E. coli (33.3% vs 6.5%) 6. Avoid if MIC >2 mg/mL, as resistance development during therapy occurs in 71.4% of cases with MIC of 8 mg/mL 6.

Complicated UTIs Without Septic Shock

• Aminoglycosides (if active in vitro) for short-duration therapy 1
• IV fosfomycin 1
• Consider plazomicin over tigecycline for carbapenem-resistant strains 1

Carbapenem-Resistant Klebsiella

For severe infections due to carbapenem-resistant Klebsiella:

1. First choice: Meropenem-vaborbactam or ceftazidime-avibactam (if active in vitro) 1
2. For metallo-beta-lactamase producers or resistance to above: Cefiderocol 1
3. Do NOT use combination therapy if the organism is susceptible to ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol 1

For non-severe carbapenem-resistant UTIs, use older antibiotics based on individual susceptibility (aminoglycosides preferred over tigecycline for UTIs) 1.

Penicillin Allergy Considerations

If true penicillin allergy exists:

• Use pivmecillinam (a beta-lactam but with different cross-reactivity profile)
• Fosfomycin (non-beta-lactam)
• Aminoglycosides for complicated UTIs
• Fluoroquinolones if susceptible (though resistance rates reach 41-47.8% in recent surveillance) 7

Avoid tigecycline for any Klebsiella infections per guidelines 1, and specifically avoid for bloodstream infections and pneumonia.

Treatment Duration

• Cystitis: 3-5 days 8
• Pyelonephritis: 7-10 days 8
• Emphysematous infections: 7-14 days adjusted per clinical response 8
• High-dose amoxicillin-clavulanate regimen: Up to 3 months with prophylactic dosing 5
• Trimethoprim-sulfamethoxazole: 6-18 months for recurrent cases in select patients 9

Critical Pitfalls

• Do NOT use new beta-lactam/beta-lactamase inhibitors (ceftazidime-avibactam, meropenem-vaborbactam) for routine ESBL infections due to stewardship concerns - reserve for carbapenem-resistant strains 1
• Klebsiella has inherently lower susceptibility to fosfomycin and nitrofurantoin compared to E. coli - always verify susceptibility before using these agents 3, 4
• Resistance can develop during amoxicillin-clavulanate therapy, especially with high baseline MICs - monitor closely 6
• Patients with diabetes, urogenital disease, or recurrent infections have higher failure rates - consider more aggressive initial therapy 10